975 results on '"Jäger, Ulrich"'
Search Results
2. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease
3. Narcissistic dimensions and depressive symptoms in patients across mental disorders in cognitive behavioural therapy and in psychoanalytic interactional therapy in Germany: a prospective cohort study
4. Affective temperament, fatigue, and pain in cancer patients
5. Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study
6. Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results
7. Reliabilität und Validität des OPD-Konfliktfragebogens bei stationären Psychotherapiepatient*innen
8. Bindung als Prädiktor von Strukturveränderungen im Verlauf von stationärer Psychotherapie
9. Integrative Beratung: Grundlagen und Perspektiven für die Praxis
10. Management of Cytokine Release Syndrome (CRS) and HLH
11. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study
12. Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial
13. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
14. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study
15. Evaluation der deutschsprachigen Kurzform des Experiences in Close Relationships Questionnaire (ECR-RD 12) im stationären Psychotherapiesetting
16. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes
17. Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma
18. Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle
19. To Be or Not to Be Improved : Patients’ Perception of Symptom Improvement – Linking the SCL-90-R to Patient-Rated Global Improvement in a Large Real-World Treatment Sample
20. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study
21. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
22. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL
23. EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies
24. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
25. Supplementary Data Figures from A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
26. Data from A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
27. Supplementary Data Tables from A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
28. CT-526 Updated Results From a Rapcabtagene Autoleucel (YTB323) Phase I Study Demonstrate Durable Efficacy and a Manageable Safety Profile in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
29. POSTER: CT-526 Updated Results From a Rapcabtagene Autoleucel (YTB323) Phase I Study Demonstrate Durable Efficacy and a Manageable Safety Profile in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
30. Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia
31. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia
32. UGT2B17 modifies drug response in chronic lymphocytic leukaemia
33. Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group
34. The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML): A representative and useful real-life data source for further biomedical research
35. Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia
36. Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial
37. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
38. Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
39. CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis
40. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy
41. A chimeric antigen receptor-based cellular safeguard mechanism for selective in vivo depletion of engineered T cells.
42. Risk as a pattern over time: Delineation of time‐dependent risk factors in biological, psychological, and social variables in cancer patients.
43. A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
44. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia
45. Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease
46. Phenotyping and Target Expression Profiling of CD34+/CD38− and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia
47. Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma
48. Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL
49. Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives
50. Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.